Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTA Reinvention Bill Introduced; Workshop Identifies Possible New Models

This article was originally published in The Gray Sheet

Executive Summary

The congressional Office of Technology Assessment would be re-established under a bill (HR 2148) introduced by Rep. Rush Holt (D-N.J.) June 13. The measure authorizes a $20 mil. appropriation in FY 2002 to resurrect OTA, which remains in existence but has been shut down since September 1995

You may also be interested in...



Sulzer Hip, Knee Surgery Patients Would Be Compensated By Profits, Insurer

Sulzer Medica is proposing to use one-half of its annual net income to help finance a nearly $100,000 cash-and-equity compensation package for hip-and-knee implant patients requiring multiple revision surgeries over the next three to five years.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel